Elligo secures $16m to scale clinical trials tech

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/	BrianAJackson)
(Image: Getty/ BrianAJackson)
Elligo Health Research has closed a $16m Series B funding round, which will help scale the company’s business and support development of new technology solutions for clinical trials.

The funding round was led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC and Excelerate Health Ventures.

Elligo did not provide any comment on the Series A round, though some of the initial investors, including Shumway Capital, did also participate in the second round, the company said.

The Series B funds will be used to expand the scale of the business “after a very successful 2016 and 2017,”​ said John Potthoff, Elligo CEO.

“In addition, we will be supporting the implementation of technology solutions with support of Saama,” ​he told us.

Elligo earlier this month​ announced a partnership with Saama Technologies through which the companies will build new technology platforms to help sponsors achieve their objectives faster, Potthoff told us at the time.

The platform will leverage Saama’s Life Science Analytics Cloud to support patient population identification based on clinical trial eligibility requirements.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Related suppliers

Follow us

Products

View more

Webinars